This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Sponsored by Denovo Biopharma LLC

About this trial

Last updated 4 years ago

Study ID

9777

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

Yes

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 19 years ago

What is this trial about?

Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.

What are the participation requirements?

Yes

Inclusion Criteria

- meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID

No

Exclusion Criteria

- meet the full syndromal criteria for other Axis I disorder

- have taken any depot antipsychotic within 4 weeks before screening

- are taking mood-stabilizing agents